Omeros is a biopharmaceutical company developing first-in-class small-molecule and protein drugs, with a core focus on the complement system. Lead programs include the MASP-2 inhibitor narsoplimab for hematopoietic stem-cell transplant–associated thrombotic microangiopathy and other lectin-pathway disorders, plus additional assets in inflammation, rare disease, and related areas. The business model centers on pipeline advancement and partnerships rather than a broad commercial portfolio.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -25.4 | — |
| Q3 2025 | 0 | — | -30.9 | — |
| Q4 2025 | 0 | — | 86.5 | — |
| Q1 2026 | 9.9 | — | 56.1 | — |
| Q2 2026 | 28.5 | — | 13.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Harmonic Inc. (HLIT), Digital Turbine, Inc. (APPS), D-Market Elektronik Hizmetler ve Ticaret A.S. (HEPS), AIR Global PLC (AIIR), Akso Health Group (AHG), Seneca Foods Corporation (SENEA)